Pearl Diagnostics will receive $1 million to evaluate the potential of a prototype assay for early detection of pneumonia caused by Pseudomonas aeruginosa.

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

Antimicrobial resistance is a growing health crisis that could lead to millions of deaths by 2050, according to the World ...

Researchers have found in a new study that common antibiotic Vancomycin may also be effective in treating individuals with a ...

Anterior Cruciate Ligament Reconstruction Improves Functional Scores and Quality of Life in Patients Older than 50 Years of ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Photodynamic inactivation using curcumin shows promise in reducing antibiotic resistance diversity in Staphylococcus aureus, ...

The inflammatory bowel disease (IBD), develops due to an incurable autoimmune liver disease called primary sclerosing ...

A study led by the University of Birmingham found that vancomycin, a commonly used antibiotic for diarrhea, could effectively ...

Diarrheagenic E. coli (DEC) is a major global cause of diarrheal diseases, with certain strains showing alarming levels of antibiotic resistance.

By combining MERFISH imaging with expansion microscopy, researchers have unlocked a new way to study bacteria at the ...

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...